tiprankstipranks
Sino Biopharmaceutical Ltd (SBMFF)
OTHER OTC:SBMFF
US Market
SBMFF
Sino Biopharmaceutical
RESEARCH TOOLSreports

Sino Biopharmaceutical (SBMFF) Stock Forecast & Price Target

43 Followers
See the Price Targets and Ratings of:

SBMFF Analyst Ratings

Strong Buy
11Ratings
Strong Buy
10 Buy
1 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Sino
Biopharmaceutical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SBMFF Stock 12 Month Forecast

Average Price Target

$1.09
▲(45.33% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Sino Biopharmaceutical in the last 3 months. The average price target is $1.09 with a high forecast of $1.40 and a low forecast of $0.89. The average price target represents a 45.33% change from the last price of $0.75.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","-1":"-$1","-0.25":"-$0.25","0.5":"$0.5","1.25":"$1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.40448,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.09,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.89376,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.89</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.748,0.7984984615384615,0.8489969230769231,0.8994953846153846,0.9499938461538462,1.0004923076923076,1.0509907692307692,1.1014892307692308,1.1519876923076922,1.2024861538461538,1.2529846153846154,1.3034830769230767,1.3539815384615383,{"y":1.40448,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.748,0.7743076923076924,0.8006153846153846,0.826923076923077,0.8532307692307692,0.8795384615384616,0.9058461538461539,0.9321538461538462,0.9584615384615385,0.9847692307692308,1.0110769230769232,1.0373846153846156,1.0636923076923077,{"y":1.09,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.748,0.7592123076923077,0.7704246153846154,0.7816369230769231,0.7928492307692308,0.8040615384615385,0.8152738461538461,0.8264861538461539,0.8376984615384615,0.8489107692307692,0.8601230769230769,0.8713353846153846,0.8825476923076923,{"y":0.89376,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.419,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.447,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.408,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.447,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.554,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.671,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.919,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.999,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.064,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.913,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.789,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.83,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.748,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$1.40Average Price Target$1.09Lowest Price Target$0.89
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
CMB International Securities Analyst forecast on SBMFF
Jill Wu
CMB International Securities
CMB International Securities
$1.11
Buy
48.11%
Upside
Reiterated
03/30/26
CMB International Securities Sticks to Their Buy Rating for Sino Biopharmaceutical (SBMFF)
Jefferies Analyst forecast on SBMFF
Chu Wang
Jefferies
Jefferies
$0.89
Buy
19.17%
Upside
Reiterated
03/30/26
Jefferies Reaffirms Their Buy Rating on Sino Biopharmaceutical (SBMFF)
BOCOM International Holdings Company Analyst forecast on SBMFF
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
$1.09→$0.98
Buy
31.08%
Upside
Reiterated
03/30/26
BOCOM International Holdings Company Sticks to Its Buy Rating for Sino Biopharmaceutical (SBMFF)
Citic Securities Analyst forecast on SBMFF
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
$1.15
Buy
53.22%
Upside
Reiterated
03/30/26
Citic Securities Keeps Their Buy Rating on Sino Biopharmaceutical (SBMFF)
UBS Analyst forecast on SBMFF
Anita Wei
UBS
UBS
$1.4
Buy
87.26%
Upside
Reiterated
03/27/26
Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (NASDAQ: ANNX), Innovent Biologics (Other OTC: IVBXF) and Sino Biopharmaceutical (Other OTC: SBMFF)
Citi Analyst forecast on SBMFF
Unknown Analyst
Citi
Not Ranked
Citi
$1.28
Buy
70.24%
Upside
Reiterated
03/27/26
Sino Biopharmaceutical (SBMFF) Gets a Buy from Citi
CICC Analyst forecast on SBMFF
Unknown Analyst
CICC
Not Ranked
CICC
$1.14
Buy
51.51%
Upside
Reiterated
03/27/26
CICC Keeps Their Buy Rating on Sino Biopharmaceutical (SBMFF)
Bank of China Analyst forecast on SBMFF
Unknown Analyst
Bank of China
Not Ranked
Bank of China
$1.02
Buy
36.19%
Upside
Reiterated
03/27/26
Sino Biopharmaceutical (SBMFF) Gets a Buy from Bank of China
Bank of America Securities Analyst forecast on SBMFF
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
$0.94
Buy
25.98%
Upside
Reiterated
03/27/26
Bank of America Securities Sticks to Their Buy Rating for Sino Biopharmaceutical (SBMFF)
Nomura Analyst forecast on SBMFF
Unknown Analyst
Nomura
Not Ranked
Nomura
$1.11
Buy
47.60%
Upside
Reiterated
03/26/26
Nomura Keeps Their Buy Rating on Sino Biopharmaceutical (SBMFF)
Bernstein Analyst forecast on SBMFF
Rebecca Liang
Bernstein
Bernstein
$1.01
Hold
34.49%
Upside
Reiterated
02/09/26
Bernstein Remains a Hold on Sino Biopharmaceutical (SBMFF)
Daiwa Analyst forecast on SBMFF
Unknown Analyst
Daiwa
Not Ranked
Daiwa
$1.28
Buy
70.24%
Upside
Reiterated
11/12/25
GF Securities Analyst forecast on SBMFF
Unknown Analyst
GF Securities
Not Ranked
GF Securities
$1.47
Buy
96.46%
Upside
Reiterated
10/14/25
HSBC Analyst forecast on SBMFF
Linda Shu
HSBC
HSBC
$1.23
Buy
63.43%
Upside
Reiterated
09/30/25
Guotai Haitong Analyst forecast on SBMFF
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
$1.28
Buy
70.24%
Upside
Reiterated
09/29/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
CMB International Securities Analyst forecast on SBMFF
Jill Wu
CMB International Securities
CMB International Securities
$1.11
Buy
48.11%
Upside
Reiterated
03/30/26
CMB International Securities Sticks to Their Buy Rating for Sino Biopharmaceutical (SBMFF)
Jefferies Analyst forecast on SBMFF
Chu Wang
Jefferies
Jefferies
$0.89
Buy
19.17%
Upside
Reiterated
03/30/26
Jefferies Reaffirms Their Buy Rating on Sino Biopharmaceutical (SBMFF)
BOCOM International Holdings Company Analyst forecast on SBMFF
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
$1.09→$0.98
Buy
31.08%
Upside
Reiterated
03/30/26
BOCOM International Holdings Company Sticks to Its Buy Rating for Sino Biopharmaceutical (SBMFF)
Citic Securities Analyst forecast on SBMFF
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
$1.15
Buy
53.22%
Upside
Reiterated
03/30/26
Citic Securities Keeps Their Buy Rating on Sino Biopharmaceutical (SBMFF)
UBS Analyst forecast on SBMFF
Anita Wei
UBS
UBS
$1.4
Buy
87.26%
Upside
Reiterated
03/27/26
Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (NASDAQ: ANNX), Innovent Biologics (Other OTC: IVBXF) and Sino Biopharmaceutical (Other OTC: SBMFF)
Citi Analyst forecast on SBMFF
Unknown Analyst
Citi
Not Ranked
Citi
$1.28
Buy
70.24%
Upside
Reiterated
03/27/26
Sino Biopharmaceutical (SBMFF) Gets a Buy from Citi
CICC Analyst forecast on SBMFF
Unknown Analyst
CICC
Not Ranked
CICC
$1.14
Buy
51.51%
Upside
Reiterated
03/27/26
CICC Keeps Their Buy Rating on Sino Biopharmaceutical (SBMFF)
Bank of China Analyst forecast on SBMFF
Unknown Analyst
Bank of China
Not Ranked
Bank of China
$1.02
Buy
36.19%
Upside
Reiterated
03/27/26
Sino Biopharmaceutical (SBMFF) Gets a Buy from Bank of China
Bank of America Securities Analyst forecast on SBMFF
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
$0.94
Buy
25.98%
Upside
Reiterated
03/27/26
Bank of America Securities Sticks to Their Buy Rating for Sino Biopharmaceutical (SBMFF)
Nomura Analyst forecast on SBMFF
Unknown Analyst
Nomura
Not Ranked
Nomura
$1.11
Buy
47.60%
Upside
Reiterated
03/26/26
Nomura Keeps Their Buy Rating on Sino Biopharmaceutical (SBMFF)
Bernstein Analyst forecast on SBMFF
Rebecca Liang
Bernstein
Bernstein
$1.01
Hold
34.49%
Upside
Reiterated
02/09/26
Bernstein Remains a Hold on Sino Biopharmaceutical (SBMFF)
Daiwa Analyst forecast on SBMFF
Unknown Analyst
Daiwa
Not Ranked
Daiwa
$1.28
Buy
70.24%
Upside
Reiterated
11/12/25
GF Securities Analyst forecast on SBMFF
Unknown Analyst
GF Securities
Not Ranked
GF Securities
$1.47
Buy
96.46%
Upside
Reiterated
10/14/25
HSBC Analyst forecast on SBMFF
Linda Shu
HSBC
HSBC
$1.23
Buy
63.43%
Upside
Reiterated
09/30/25
Guotai Haitong Analyst forecast on SBMFF
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
$1.28
Buy
70.24%
Upside
Reiterated
09/29/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sino Biopharmaceutical

3 Months
xxx
Success Rate
3/3 ratings generated profit
100%
Average Return
+46.57%
reiterated a xxx
 rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +46.57% per trade.
1 Year
Ziyi ChenGoldman Sachs
Success Rate
2/2 ratings generated profit
100%
Average Return
+15.50%
reiterated a buy rating 9 months ago
Copying Ziyi Chen's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +15.50% per trade.
2 Years
xxx
Success Rate
2/3 ratings generated profit
67%
Average Return
+22.23%
reiterated a xxx
 rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +22.23% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SBMFF Analyst Recommendation Trends

Rating
Oct 25
Nov 25
Jan 26
Feb 26
Mar 26
Strong Buy
20
10
4
2
11
Buy
0
0
0
0
0
Hold
7
5
5
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
27
15
9
3
12
In the current month, SBMFF has received 11 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. SBMFF average Analyst price target in the past 3 months is 1.09.
Each month's total comprises the sum of three months' worth of ratings.

SBMFF Financial Forecast

SBMFF Earnings Forecast

Next quarter’s earnings estimate for SBMFF is $0.02 with a range of $0.02 to $0.02. The previous quarter’s EPS was <$0.01. SBMFF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year SBMFF has Performed in-line its overall industry.
Next quarter’s earnings estimate for SBMFF is $0.02 with a range of $0.02 to $0.02. The previous quarter’s EPS was <$0.01. SBMFF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year SBMFF has Performed in-line its overall industry.

SBMFF Sales Forecast

Next quarter’s sales forecast for SBMFF is $2.93B with a range of $2.93B to $2.93B. The previous quarter’s sales results were $1.99B. SBMFF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year SBMFF has Performed in-line its overall industry.
Next quarter’s sales forecast for SBMFF is $2.93B with a range of $2.93B to $2.93B. The previous quarter’s sales results were $1.99B. SBMFF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year SBMFF has Performed in-line its overall industry.

SBMFF Stock Forecast FAQ

What is SBMFF’s average 12-month price target, according to analysts?
Based on analyst ratings, Sino Biopharmaceutical Ltd’s 12-month average price target is 1.09.
    What is SBMFF’s upside potential, based on the analysts’ average price target?
    Sino Biopharmaceutical Ltd has 45.33% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SBMFF a Buy, Sell or Hold?
          Sino Biopharmaceutical Ltd has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Sino Biopharmaceutical Ltd’s price target?
            The average price target for Sino Biopharmaceutical Ltd is 1.09. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $1.40 ,the lowest forecast is $0.89. The average price target represents 45.33% Increase from the current price of $0.75.
              What do analysts say about Sino Biopharmaceutical Ltd?
              Sino Biopharmaceutical Ltd’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of SBMFF?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.